Gene

ABL1

ABL proto-oncogene 1, non-receptor tyrosine kinase

Explore in graph →CI-GENE-00000153HGNC:76 ENSG00000097007 NCBI 25 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (617)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 301–350 of 617 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ABL1 G250E + ABL1 Fusion7
Imatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2

Cohorts

Alteration frequency by cohort (122)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved122 cohort rows (showing 22, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Breast Cancer (MSK, Nat Genet 2025) breast_msk_2025	Invasive Breast Carcinoma	Ssm	31

Literature

Linked publications (65)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 65 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
· Oncogene · 2002 · PMID 12476305 · validated civic_curation pubmed
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
· Leuk Res · 2010 · PMID 20537386 · validated civic_curation pubmed
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
· N Engl J Med · 2014 · PMID 25207766 · validated civic_curation pubmed
Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia.
· Oncotarget · 2017 · PMID 27894077 · validated civic_curation pubmed

ABL1 G398R + ABL1 Fusion3
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4560 In an in vitro study, a Ba/F3 murine cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 48.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	accepted	EID4561 In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.27nM vs… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Nilotinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2864 In an in vitro study, a Ba/F3 cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 gene fusion was associated with sensitivity to nilotinib treatment (IC50: 0.49-fold), c… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic

ABL1 G398R + ABL1 Fusion3

Bosutinib

Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS

Predictive

Supports Sensitivity Response

submitted

EID4560

In an in vitro study, a Ba/F3 murine cell line stably expressing the G398R mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to bosutinib treatment (IC50: 48.… (full text at CIViC)

PMID 19075254 · Redaelli et al., 2009 · Open in CIViC

ABL1 H396P + ABL1 Fusion11
Axitinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Does Not Support Resistance	2	accepted	EID7770 In a proliferation assay measuring tritiated thymidine incorporation in the presence of axitinib, Ba/F3 cells carrying the BCR-ABL1 variant showed lower incorporation when harboring fusions with the H… (full text at CIViC) PMID 25686603 · Pemovska et al., 2015 · Open in CIViC	civic
Bosutinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Does Not Support Resistance	2	accepted	EID4554 In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC) PMID 21865346 · Cortes et al., 2011 · Open in CIViC	civic
〃	Acute Lymphoblastic Leukemia	Predictive	D	Does Not Support Resistance	2	submitted	EID4379 In an in vitro kinase study, the recombinant ABL1 H396P mutant kinase did not demonstrate resistance to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 1 and 1) when compared to wil… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4555 In an in vitro study, a Ba/F3 murine cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to bosutinib treatment … (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
Dasatinib	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	C	Supports Sensitivity Response	2	submitted	EID4556 In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC) PMID 19779040 · Müller et al., 2009 · Open in CIViC	civic
〃	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID9084 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with increased sensitivity to dasatinib treatment (IC50: 8.9 nM) as co… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4557 In an in vitro study, a Ba/F3 cell line stably expressing the H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (IC50: 1.95nM vs.… (full text at CIViC) PMID 19075254 · Redaelli et al., 2009 · Open in CIViC	civic
〃	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID4558 In an in vitro study, a Ba/F3 cell line expressing a H396P mutation in the ABL1 portion of the BCR-ABL1 fusion protein was associated with sensitivity to dasatinib treatment (0.6 nmol/L vs. 0.8 nmol/L… (full text at CIViC) PMID 15930265 · O'Hare et al., 2005 · Open in CIViC	civic
Imatinib	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	accepted	EID7847 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to imatinib treatment (IC50: >2000.0 nM) as compared t… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
Imatinib Mesylate + NilotinibCombination	Chronic Myeloid Leukemia, BCR-ABL1 PositiveALIAS	Predictive	D	Supports Resistance	2	accepted	EID6240 In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC) PMID 16772610 · Bradeen et al., 2006 · Open in CIViC	civic
Bafetinib + NilotinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Does Not Support Resistance	3	accepted	EID7846 In an in vitro study, a Ba/F3 cell line stably expressing H396P in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to nilotinib and bafetinib (INNO-406) treatme… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic